With a $27.8 billion acquisition under fire from the Federal Trade Commission, the biopharmaceutical giant Amgen Inc. in May 2023 called in David R. Marriott, a Cravath, Swaine & Moore LLP partner who specializes in litigating complex disputes.
By September 2023, Marriott had secured a consent order that ended all litigation and cleared the path for the deal to close. It was “a rare instance” of the FTC “throwing in the towel on litigat...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In